Nabnita Patnaik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nabnita Patnaik has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Arvind Kumar Morya
All India Institute of Medical Sciences
1 shared publication - Ashoo Grover
Indian Council of Medical Research, New Delhi, India
1 shared publication E. Prabhakar Reddy
CEO & Professor of Biochemistry, Anna Gowri Medical College and Hospital, Parameswaramangalam, Puttur, Tirupati District, Andhra Pradesh, India.
1 shared publication- Hemanth Raj Thangappazham
Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, USA.
1 shared publication - Kalpana Ramanna Mali
Department of Pharmacology, Neelima Institute of Medical Sciences, Hyderabad, India
1 shared publication - Kishore Yadav
All India Inst Med Sci, Dept Community & Family Med, Bibinagar, India
1 shared publication
Latest Publications
- Open Access
- 20 February 2025
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 71 (2) , 74-79
Impact of metformin therapy on serum visfatin levels in polycystic ovary syndrome: a systematic review and randomized permuted meta-analysis
Visfatin, an, is associated with reproductive and metabolic disorders like polycystic ovary syndrome (PCOS). Although visfatin levels are known to be elevated in PCOS, the effect of metformin treatment on these levels remains unclear. This meta-analysis aimed to assess changes in circulating visfatin levels before and after metformin intervention in PCOS patients. Relevant studies were identified through comprehensive searches, and a random-effects meta-analysis was conducted to calculate standardized mean differences (SMDs) with 95% confidence intervals (CIs). Sensitivity analysis and randomized permuted meta-analyses (with 1,000, 10,000, and 100,000 iterations) were performed to validate the findings. The analysis included four studies and showed a significant reduction in visfatin levels following metformin treatment (SMD: -0.45, 95% CI: -0.76 to -0.14, p = 0.0043). These results highlight metformins impact on visfatin levels in PCOS, though larger trials are needed to further explore visfatins role as a therapeutic target in PCOS.
- 20 February 2025
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 71 (2) , 74-79
Open AccessImpact of metformin therapy on serum visfatin levels in polycystic ovary syndrome: a systematic review and randomized permuted meta-analysis
Visfatin, an, is associated with reproductive and metabolic disorders like polycystic ovary syndrome (PCOS). Although visfatin levels are known to be elevated in PCOS, the effect of metformin treatment on these levels remains unclear. This meta-analysis aimed to assess changes in circulating visfatin levels before and after metformin intervention in PCOS patients. Relevant studies were identified through comprehensive searches, and a random-effects meta-analysis was conducted to calculate standardized mean differences (SMDs) with 95% confidence intervals (CIs). Sensitivity analysis and randomized permuted meta-analyses (with 1,000, 10,000, and 100,000 iterations) were performed to validate the findings. The analysis included four studies and showed a significant reduction in visfatin levels following metformin treatment (SMD: -0.45, 95% CI: -0.76 to -0.14, p = 0.0043). These results highlight metformins impact on visfatin levels in PCOS, though larger trials are needed to further explore visfatins role as a therapeutic target in PCOS.
- Open Access
- 25 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32937
Face Mask in COVID-19 and Its Association With Dry Eye Disease: A Cross-Sectional Study
Aim: To determine whether wearing a face mask for more than three to six hours/day leads to the new onset of symptoms or worsening of pre-existing dry eye disease (DED) in healthcare workers (HCWs) of our institute. Methodology: An observational cross-sectional study, where 114 HCWs using face masks regularly participated voluntarily in the study. A survey with a modified Ocular Surface Disease Index (OSDI) questionnaire was completed by participants. They were divided into groups based on their sex, age, how long they had been wearing face masks, and whether they had a history of DED. Results: We found that for HCWs who had previously experienced DED and who were under the age of 40, wearing a face mask for more than three to six hours/day could contribute to or worsen symptoms of DED. Also, we observed that the N-95 mask has a higher chance of causing DED than surgical masks. Conclusion: Medical professionals need to be aware of any potential dry eye symptoms related to the prolonged use of a face mask. Additional consideration should be given to patients who already have DED. The possible concerns that incorrectly fitted facemasks may cause to the health of their ocular surface should be discussed with patients by ophthalmologists. Future research involving larger populations will shed light on the prevalence and scope of the mask-associated dry eye problem.
- 25 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32937
Open AccessFace Mask in COVID-19 and Its Association With Dry Eye Disease: A Cross-Sectional Study
Aim: To determine whether wearing a face mask for more than three to six hours/day leads to the new onset of symptoms or worsening of pre-existing dry eye disease (DED) in healthcare workers (HCWs) of our institute. Methodology: An observational cross-sectional study, where 114 HCWs using face masks regularly participated voluntarily in the study. A survey with a modified Ocular Surface Disease Index (OSDI) questionnaire was completed by participants. They were divided into groups based on their sex, age, how long they had been wearing face masks, and whether they had a history of DED. Results: We found that for HCWs who had previously experienced DED and who were under the age of 40, wearing a face mask for more than three to six hours/day could contribute to or worsen symptoms of DED. Also, we observed that the N-95 mask has a higher chance of causing DED than surgical masks. Conclusion: Medical professionals need to be aware of any potential dry eye symptoms related to the prolonged use of a face mask. Additional consideration should be given to patients who already have DED. The possible concerns that incorrectly fitted facemasks may cause to the health of their ocular surface should be discussed with patients by ophthalmologists. Future research involving larger populations will shed light on the prevalence and scope of the mask-associated dry eye problem.